Top Page
Race Oncology Ltd.
(Sydney:RAC)
Race Oncology Ltd. (RAC) vs. iShares MSCI Australia ETF (EWA)
Race Oncology Ltd. Business Overview & Revenue Model
Race Oncology Ltd. Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.00M | 3.13M | 707.81K | 387.38K | 159.37K | Gross Profit |
| 1.39M | 2.85M | 426.61K | 106.19K | -121.83K | EBIT |
| -13.38M | -12.99M | -11.49M | -6.48M | -3.96M | EBITDA |
| -14.20M | -12.78M | -11.63M | -6.45M | -3.72M | Net Income Common Stockholders |
| -13.82M | -9.92M | -11.20M | -6.34M | -3.85M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 17.19M | 21.52M | 33.54M | 9.32M | 1.73M | Total Assets |
| 20.23M | 26.64M | 37.52M | 14.25M | 5.93M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -17.19M | -1.92M | -6.04M | -9.32M | -1.73M | Total Liabilities |
| 1.92M | 1.15M | 1.42M | 523.11K | 243.65K | Stockholders Equity |
| 18.31M | 25.49M | 36.11M | 13.72M | 5.69M |
| Cash Flow | Free Cash Flow | |||
| -9.55M | -10.65M | -6.26M | -4.70M | -2.46M | Operating Cash Flow |
| -9.55M | -10.65M | -6.26M | -4.70M | -2.46M | Investing Cash Flow |
| 0.00 | 7.90M | -1.00 | 0.00 | 0.00 | Financing Cash Flow |
| 5.21M | -1.28M | 30.51M | 12.28M | 3.21M |
Race Oncology Ltd. Technical Analysis
Race Oncology Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $8.62B | 171.13 | 14.52% | ― | 55.85% | 893.42% | |
56 Neutral | AU$38.25M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | AU$246.70M | ― | -37.20% | ― | ― | 32.02% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
37 Underperform | $126.94M | ― | -99.05% | ― | ― | -34.09% | |
36 Underperform | AU$3.32M | ― | -119.28% | ― | ― | 64.10% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
Race Oncology Ltd. Corporate Events
Race Oncology has announced the appointments of Dr. Jose Iglesias as Chief Medical Officer and Dr. Simon Fisher as Vice President of Clinical, both bringing extensive experience in oncology and pharmaceutical leadership. These appointments are expected to significantly enhance Race’s clinical leadership and strategic capabilities, particularly in advancing the development of their oncology drug, RC220, which aims to address significant gaps in patient care and improve outcomes in cancer treatment.
Race Oncology Ltd has successfully and safely dosed the first patient in its Phase 1 clinical trial of RC220 for advanced solid tumours at the Southside Cancer Care Centre in Australia. This milestone marks the beginning of a program to assess the safety, tolerability, and therapeutic potential of RC220, with plans to recruit up to 32 more patients across Australia, Hong Kong, and South Korea. The trial aims to determine the maximum tolerated dose of RC220 in combination with doxorubicin and will use a Bayesian design for greater flexibility and speed. The outcome of this trial could impact Race Oncology’s positioning in the cancer treatment market and provide new options for patients with advanced solid tumours.
Race Oncology Ltd has made significant strides in its Phase 1 clinical trial of RC220 in combination with doxorubicin for patients with advanced solid tumors. The company received ethics and regulatory approvals for trial sites, with patient screening underway and treatment expected to begin soon. The company is financially stable with $17.12 million in cash, ensuring funding for its clinical programs through CY2026. Additionally, Race Oncology was added to the All Ordinaries Index, highlighting its growing presence in the Australian equities market.
Race Oncology Ltd has announced the activation of a second site for its Phase 1 clinical trial of RC220, in combination with doxorubicin, targeting advanced solid tumors at the Central Coast Local Health District in Australia. This expansion is expected to accelerate patient recruitment and data collection on safety, tolerability, and pharmacokinetics, potentially enhancing Race’s position in the oncology market by providing insights into the cardioprotective and anticancer efficacy of RC220.
Race Oncology Ltd has announced the activation of the Southside Cancer Care Centre in Miranda, NSW, as the first Australian site for its Phase 1 clinical trial of RC220 in combination with doxorubicin for advanced solid tumors. This trial aims to gather safety, tolerability, and pharmacokinetic data, and assess the maximum tolerated dose and potential anticancer efficacy of RC220. The trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, using a Bayesian design for greater flexibility. This development marks a significant step in Race Oncology’s efforts to advance RC220 as a promising cancer treatment, potentially improving therapy outcomes while reducing side effects for patients.
Race Oncology Ltd has received human ethics approval from the Bellberry Human Research Ethics Committee to commence its Phase 1 clinical trial of RC220 at Gosford and Wyong Hospitals. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of RC220, both alone and in combination with doxorubicin, in patients with solid tumors. The approval marks a significant milestone for Race Oncology, as it is the second site to receive such approval, following the Southside Cancer Centre. This progress is expected to bolster the company’s momentum in advancing its clinical program and potentially enhance its position in the oncology market.
Race Oncology has initiated its first Australian clinical site at Southside Cancer Care Centre in Miranda, NSW, for a Phase 1 trial of RC220 in combination with doxorubicin for advanced solid tumours. This trial, which will be conducted across multiple sites in Australia, Hong Kong, and South Korea, aims to evaluate the safety, pharmacokinetics, and maximum tolerated dose of RC220, while also assessing its cardioprotective and anticancer efficacy. The initiation marks a significant step towards Race’s mission to provide innovative cancer treatments, with the trial designed to offer flexibility and speed through a Bayesian approach. The company plans to provide regular updates on the trial’s progress.
Race Oncology Ltd. is on the brink of several critical data and value inflection points with the imminent start of an open-label clinical trial for their drug RC220 this quarter. The company is increasing its focus on the health of cancer survivors and anticipates significant news flow throughout 2025, which is expected to drive positive sentiment in the sector.
Race Oncology Ltd has announced the approval of a Phase 1 clinical trial for its reformulated bisantrene, RC220, by the Bellberry Human Research Ethics Committee. This trial will evaluate the safety and efficacy of RC220 in combination with doxorubicin, focusing on cardiac and clinical biomarkers. The company is hosting an online investor briefing to discuss the trial details, aiming to strengthen its position in the oncology market by addressing high unmet needs and exploring partnerships to expand access to its treatments.
Race Oncology Ltd has received ethics approval from the Bellberry Human Research Ethics Committee to initiate a Phase 1 clinical trial of RC220 bisantrene, both alone and in combination with doxorubicin, for patients with solid tumors. This approval marks a significant milestone, enabling the company to begin patient enrollment at the Southside Cancer Care Centre in March 2025, with plans to expand to additional sites. The trial’s success could enhance Race Oncology’s position in the industry by advancing their cardioprotective cancer therapies, potentially benefiting stakeholders through improved treatment options.
Race Oncology Ltd has executed an $8.6 million contract with George Clinical International to support a Phase 1 trial of RC220 bisantrene in combination with doxorubicin for patients with advanced tumors in Australia, Hong Kong, and South Korea. This trial aims to assess the safety, pharmacokinetics, and maximum tolerated dose of the combination, with initial data on its cardioprotective and anticancer effects. The trial’s success could enhance Race’s positioning in the oncology market by offering a novel treatment that mitigates heart damage from anthracyclines while improving cancer treatment.